NUVILEX INC (NVLX)

0.14
0.00 0.69
OTC
Prev Close 0.14
Open 0.14
Day Low/High 0.14 / 0.15
52 Wk Low/High 0.10 / 0.33
Volume 3.32M
Exchange OTC
Shares Outstanding 699.29M
Market Cap 136.36M
Div & Yield N.A. (N.A)

Latest News

Nuvilex Announces Name Change To PharmaCyte Biotech

Nuvilex To Attend 2015 Gastrointestinal Cancers Symposium In San Francisco, January 15-17, 2015

Nuvilex Announces Name Change To PharmaCyte Biotech

Company's Shares Will Trade Under New Ticker Symbol PHCB

GlobeNewswire

Nuvilex To Attend 2015 Gastrointestinal Cancers Symposium In San Francisco, January 15-17, 2015

GlobeNewswire

FDA Grants Orphan Drug Designation To Nuvilex For Pancreatic Cancer Treatment

GlobeNewswire

Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation In New Facility

GlobeNewswire

Nuvilex Provides Shareholder Update On Cancer And Diabetes Programs

GlobeNewswire

Nuvilex Provides Update On Significance Of Austrianova's CGMP Live-Cell Encapsulation Facility

GlobeNewswire

Nuvilex Announces Name Change Of Subsidiary To Viridis Biotech

GlobeNewswire

Nuvilex Announces The Opening Of Austrianova's CGMP Live Cell Encapsulation Facility In Thailand

GlobeNewswire

Nuvilex Obtains Exclusive Worldwide License To Develop Disease Treatments That Combine Cell-in-a-Box(R) And Cannabinoid-Based Medicine

GlobeNewswire

Nuvilex Announces The Formation Of A Diabetes Consortium For The Development Of Its Treatment For Insulin-Dependent Diabetes

GlobeNewswire

Nuvilex Executives In Southeast Asia To Further Advance Cell-in-a-Box Technology(R)

GlobeNewswire

Nuvilex Announces Preliminary Data From Preclinical Study Of Effects Of Its Pancreatic Cancer Treatment On Ascites Fluid Formation

GlobeNewswire

Nuvilex Applies In Australia For The Orphan Drug Designation For Pancreatic Cancer Treatment

GlobeNewswire

Nuvilex Contracts With University Of Veterinary Medicine In Vienna To Conduct Preclinical Studies On The Use Of Cell-in-a Box(R) To Develop Diabetes Treatment

GlobeNewswire

Nuvilex Secures Worldwide License For Insulin-Producing Cells From University Of Technology, Sydney, For Use In Developing Diabetes Treatment

GlobeNewswire

Nuvilex Applies To FDA For Orphan Drug Designation For Its Cell-in-a-Box(R) Treatment For Pancreatic Cancer

GlobeNewswire

Nuvilex Appoints Dr. Matthias Lohr As Chairman Of Scientific Advisory Board

GlobeNewswire

Nuvilex Announces Strategic Changes To Leadership Team And Appoints Prof. Dr. Walter H. Gunzburg As Chief Scientific Officer

GlobeNewswire

Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use Of Cell-in-a-Box(R) For Treatment Of Diabetes

GlobeNewswire

Nuvilex Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes

GlobeNewswire

Nuvilex Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes

GlobeNewswire

Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award In Singapore

GlobeNewswire

Nuvilex Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-in-a-Box(R) Treatment For Pancreatic Cancer

GlobeNewswire

Nuvilex Begins Preclinical Studies With Translational Drug Development To Determine If Nuvilex's Unique Cancer Treatment Can Slow Accumulation Of Malignant Ascites Fluid

GlobeNewswire

Nuvilex Announces Publication Of Combined Results Of The Initial Phase 1/2 Clinical Trial And A Second Phase 2 Clinical Trial Of The Cell-in-a-Box(R) Plus Ifosfamide Combination In Patients With Advanced, Inoperable Pancreatic Cancer

GlobeNewswire

Nuvilex Provides Update On Status Of Preclinical Studies At Translational Drug Development

GlobeNewswire

Nuvilex Announces That Dr. Richard M. Hyslop Will Present At The ACS Annual Meeting On "Sustainable, Green Chemistry And Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."

GlobeNewswire

Nuvilex And Austrianova Announce Results Of Clinical Trial In Dogs With Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide

GlobeNewswire

Nuvilex Provides Shareholder Update On Milestone Accomplishments

GlobeNewswire

Nuvilex Scheduled To Begin Preclinical Studies In Early August

Preparations for Preclinical Studies on the Effect of Nuvilex's Pancreatic Cancer Treatment on Ascites Fluid Accumulation Completed

GlobeNewswire

Watchlist

Trending
Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles
Caterpillar Erases Gains Despite Strong Quarterly Results and Raised Forecast
Micron's Stock Is Trading Real Ugly
Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash
CHART: Here's How Much Apple Stock Has Lost in Value in the Last Five Days